Country: United States
Language: English
Source: NLM (National Library of Medicine)
TRIAMCINOLONE ACETONIDE (UNII: F446C597KA) (TRIAMCINOLONE ACETONIDE - UNII:F446C597KA)
REMEDYREPACK INC.
TOPICAL
PRESCRIPTION DRUG
Triamcinolone acetonide cream USP, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following sizes: 15 g tube (NDC: 52565-056-15) 30 g tube (NDC: 52565-056-30) 80 g tube (NDC: 52565-056-80) 1 lb jar (454 grams) (NDC: 52565-056-26) Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat. Protect from freezing. Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 PI-056-00 Rev 06/2019
Abbreviated New Drug Application
TRIAMCINOLONE ACETONIDE- TRIAMCINOLONE ACETONIDE CREAM REMEDYREPACK INC. ---------- TRIAMCINOLONE ACETONIDE CREAM USP, 0.1% RX ONLY DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone Acetonide Cream USP, 0.1% contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione, 9- fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis- (oxy)]-, (11β,16α)-], with the empirical formula C H FO and molecular weight 434.50. CAS 76-25-5. Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of triamcinolone acetonide per gram in a base containing emulsifying wax, cetyl alcohol, isopropyl palmitate, sorbitol solution, glycerin, lactic acid, benzyl alcohol and purified water. CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. PHARMACOKINETICS The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar Read the complete document